'Tis the Season for a Flu Test
Executive Summary
With the introduction of two new drugs for fighting the flu, the diagnostic tests for influenza become all the more important. Several niche players are hoping that physicians will use the tests to determine which patients have the flu in order to determine how to treat them. But for drug companies eager for as many patients as possible to use their therapies, the tests are a mixed blessing. They might help drug companies score points with payers, eager to curb the costs of treating an unpleasant but not usually serious disease, but they also help to limit the use of the drug to only those people who have the flu.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.